baber/WOPTO huggingface dataset:
Patent NZ-506281-A (NZ)
Title: Application of an aqueous dispersion of zinc borate in the preservation of wood composite products
Inventor: FOOKES DAVID
IPC: B27N3/02
Filed: 1999-02-02
Abstract: The resistant biological degradation of composite wood products is improved by applying a suitable aqueous dispersion of zinc borate onto the fibres to uniformly distribute and to adhere the zinc borate to the strands of the wood composite, applying a suitable adhesive to the wood strands, forming a strand lay-up and consolidating a lay-up under heat and pressure to form a consolidated product with zinc borate uniformly distributed there through.
Patent NZ-512611-A (NZ)
Title: Milling apparatus
Inventor: NALDER ALLAN NEWTON
IPC: B27B7/00
Filed: 2001-06-27
Abstract: A portable milling apparatus used to mill a log which includes;  a guide adapted to be attached to a log, the guide including a pair of beams defining a ladder with a plurality of rungs positioned between each of said beams disposed along the length of said beams, and a fixing means adapted to fix a guide on substantially the top and/or the side of a log to be milled, and a carriage adapted to move along the guide and to receive a cutting blade.
Patent NZ-513037-A (NZ)
Title: Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
Inventor: HUBER GERALD
IPC: A61K9/20
Filed: 1999-01-29
Abstract: A pharmaceutical composition for the slow release of an active agent in the gastrointestinal tract comprises a plurality of particles which contain an active agent and which are coated with a material that is insoluble in gastrointestinal juice. The particles have a core consisting of a homogenous mixture comprising a pharmaceutical active agent and a polymer which is insoluble in gastrointestinal juice, with a maximum average inner pore diameter not exceeding 35 mm or has a percent porosity not exceeding 27%. .
Patent NZ-514719-A (NZ)
Title: Tape comprising zones of ferrous material fixed on the tape or within the tape
Inventor: TSENG DA
IPC: H01F41/34
Filed: 2001-10-24
Abstract: A ferrous tape for making Ferro-Stickers including an adhesive tape, a plurality of zones of ferrous materials exposed on the tape, or embedded in the tape; wherein the distance between each ferrous zone and its adjacent ferrous zone is the same.
Patent NZ-516778-A (NZ)
Title: Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one
Inventor: MOON KWANG YUL
IPC: C07D207/18
Filed: 1999-03-04
Abstract: A process for the production of a compound of formula (9) or a pharmaceutically acceptable salt thereof, comprising the reaction of a compound of formula (2), with a compound of formula (10), wherein; X is a leaving group; R is alkyl, haloalkyl or a salt thereof; The compound of formula (2) is the product of a reaction of formula (1), with a compound of formula R-ONH2, followed by deprotection of the amino groups and optional salt formation wherein; Formula (1) is produced by a process comprising reaction of a compound of formula (5) with a Raney-Nickel catalyst to produce a compound of formula (6), protecting the amino group of (6) to produce (7) and reduction of the double bond to produce the compound of formula (1), wherein; P1 and P2 are protecting groups.
Patent NZ-518458-A (NZ)
Title: Isolate DNA polymerase lambda and uses thereof
Inventor: BLANCO DAVILA LUIS
IPC: G01N33/53
Filed: 2000-10-02
Abstract: Isolated DNA polymerase lambda (Pol ë), nucleotide sequence of the human gene for DNA polymerase lambda (Pol lambda), the amino acid sequence of Pol lambda, and the amino acid sequence of several isoforms derived from alternative splicing of its mRNA are disclosed. The association of some of these isoforms with tumour samples makes Pol lambda a marker for the diagnosis, prognosis and evolution of tumoral processes.
Patent NZ-519669-A (NZ)
Title: Streptococcus pyogenes virulence genes and proteins and their use
Inventor: CLARKE ENDA ELIZABETH
IPC: A61P31/04
Filed: 2000-12-22
Abstract: A series of genes involved in citrate fermentation from Streptococcus pyogenes are shown to encode products that are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application
Patent NZ-519936-A (NZ)
Title: Antibodies to human Interleukin-1
Inventor: GRAM HERMANN
IPC: A61P37/06
Filed: 2001-01-19
Abstract: An antibody to IL-1b has an antigen binding specificity for an antigenic epitope of mature human IL-1b, includes the loop comprising residues Gly 22, Pro 23, Tyr 24 and Glu 25 and is capable of inhibiting the binding of IL-1b to its receptor. Preferably the antibody comprises an antigen binding site comprising at least one immunoglobin heavy chain variable domain (VH) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3 as shown in SEQ ID NO:1, i.e. CDR-1 having the amino acid sequence Ser-Tyr- Trp-Ile-Gly , CDR2 having the amino acid sequence Ile-Ile- Tyr-Pro-Ser-Asp-Ser-Asp-Thr-Arg-Tyr-Ser-Pro-Ser-Phe-Gln-Gly and the CDR 3 having the amino acid sequence Tyr-Thr-Asn- Trp-Asp-Ala-Phe-Asp-Ile. The antibody can be used in the manufacture of a medicament for the prevention or treatment of a an IL-mediated disease or disorder, allergies and allergic conditions, hypersensitivity reactions, autoimmune diseases, severe infections, organ or tissue transplant rejection; autoimmune disease, arthritis, rheumatoid arthritis, arthritis chronica progrediente, arthritis deformans, rheumatic diseases, inflammatory pain, hypersensitivity, airways hypersensitivity, dermal hypersensitivity, allergies, haematological disorders, hemolytic anaemia, aplastic anaemia, pure red cell anaemia, idiopathic thrombocytopenia, systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease, ulcerative colitis, Crohn's disease, Irritable Bowel Syndrome, endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes, diabetes mellitus type I, uveitis (anterior and posterior), keratoconjunctivitis sicca, vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis, idiopathic nephrotic syndrome or minimal change nephropathy, asthma, bronchitis, pneumoconiosis, pulmonary emphysema, and other obstructive or inflammatory diseases of the airways, acute and hyperacute inflammatory reactions, acute infections, septic shock, endotoxic shock, adult respiratory distress syndrome, meningitis, pneumonia; and severe burns, cachexia or wasting syndrome, cancer, organ dysfunction, AIDS- related cachexia, diseases of bone metabolism, osteoarthritis, osteoporosis and other inflammatory arthritides, bone loss in general, age-related bone loss, periodontal disease, cancers, and IL-1-dependent tumours. Also described is a DNA construct that encodes a heavy chain which comprises a first part which encodes a variable chain comprising alternatively framework and hypervariable regions and a second part encoding a heavy chain constant part, and another DNA constant encoding a light chain.
Patent NZ-526133-A (NZ)
Title: Geldanamycin derivative and method of treating cancer using same
Inventor: SNADER KENNETH M
IPC: A61K31/395
Filed: 2002-03-28
Abstract: A geldanamycin derivative of formula I, or a pharmaceutically acceptable salt thereof, is described to be used in the manufacture of a medicament for treating or preventing cancer. When n=1, each of R1 and R2 is disclosed to be hydrogen, and, when n=0, a double-bond exists between C4 and C5. R3 and R4 are stated to be hydrogen or hydroxyl; wherein, when R3 is hydrogen, R4 is hydroxyl, and when R3 is hydroxyl, R4 is hydrogen. R5 is hydrogen or a group of formula II, wherein each of R6, R7, and R8 is independently selected from the group consisting of hydrogen, halo, azido, nitro, a C1-C8 alkyl, a C1-C8 alkoxy, aryl, cyano, and NR10R11, wherein each of R10 and R11 is independently selected from the group consisting of hydrogen and a C-1-C3 alkyl. The derivative is explained to exhibit significant preliminary in vitro activity, particularly significant oral in vitro activity.
Patent NZ-528199-A (NZ)
Title: Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
Inventor: GRILLO-LOPEZ ANTONIO
IPC: C02F1/00
Filed: 1999-08-11
Abstract: An anti-CD20 antibody can be used for the manufacture of a medicament for reducing the risk of relapse of B-cell lymphoma. Preferably the antibody is radiolabeled. (62) Divided out of 509962
Patent NZ-529877-A (NZ)
Title: Antineoplastic combinations
Inventor: DUKART GARY
IPC: A61K33/243
Filed: 2002-05-29
Abstract: Disclosed herein is a use of a rapamycin derivative and an antineoplastic alkylating agent in the preparation of a medicament for the treatment of a neoplasm, wherein the neoplasm is soft tissue sarcoma or colon cancer. Preferably the rapamycin derivative is rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methyl propionic acid (CCI-779), and the antineoplastic alkylating agent is selected from the group consisting of cyclophosphamide, carmustine, and cisplatin.
Patent NZ-533785-A (NZ)
Title: Piperidine derivatives their preparation and their use in the treatment of condition mediated by tachykinins
Inventor: ALVARO GIUSEPPE
IPC: A61P25/24
Filed: 2003-02-10
Abstract: Disclosed are piperidine derivatives of formula (I), wherein R represents halogen or C1-4 alkyl; R1 represents C1-4 alkyl; R2 or R3 independently represent hydrogen or C1-4 alkyl; R4 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen; R5 represents hydrogen , C1-4 alkyl or C3-7 cycloalkyl; R6 is hydrogen and R7 is a radical of formula (W): R6 is a radical of formula (W) and R7 is hydrogen; X represents CH2, NR5 or O; Y represents Nitrogen and Z is CH or Y represents CH and Z is Nitrogen; A represents C(O) or S(O)q, provided that when Y is nitrogen and Z is CH, A is not S(O)q; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p and q are independently an integer from 1 to 2; and pharmaceutically acceptable salts and solvates thereof. The process for their preparation and their use in the treatment of condition mediated by tachykinins are also disclosed.
Patent NZ-535546-A (NZ)
Title: Non-steroidal progesterone receptor modulators
Inventor: LUCAS HANS
IPC: A61P43/00
Filed: 2003-04-01
Abstract: Disclosed is a compound according to general formula I wherein the substituents are as described in the specification. Compounds of the type disclosed are progesterone receptor modulators useful for treatment of gynaecological disorders, breast cancer, and luteal support during IVF amongst others.
Patent NZ-550026-A (NZ)
Title: Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
Inventor: ZELDIS JEROME B
IPC: A61K31/59
Filed: 2005-03-18
Abstract: Disclosed is the use of 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, to treat scleroderma.
Patent NZ-550268-A (NZ)
Title: Tetrahydroquinoline derivatives and a process for preparing the same
Inventor: KUBOTA HITOSHI
IPC: C07D413/14
Filed: 2005-04-01
Abstract: Disclosed are tetrahydroquinoline derivatives of formula (I) wherein the substituents are as described in the specification and methods of producing them. The compounds of the invention are cholesteryl ester transfer protein (CETP) inhibitors useful in the treatment of arteriosclerosis, peripheral vascular disease, dyslipidemia,hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial- ypercholesterolemia, cardiovascular diseases, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, restenosis after angioplasty, hypertension, cerebral infarction, cerebral stroke, diabetes, vascular complication of diabetes, thrombotic diseases, obesity and endotoxemia.
Patent NZ-551822-A (NZ)
Title: A method of producing a triglyceride solution from plants or seeds by using fatty acid alkyl esters
Inventor: CHOU CHIH-CHUNG
Filed: 2006-12-04
Abstract: A method of producing a triglyceride solution is disclosed, which comprises contacting a liquid fatty acid alkyl ester and a part of oil-bearing plant containing triglyceride (particularly seeds) so that the triglyceride is dissolved into the fatty acid alkyl ester to form a triglyceride solution. Preferred fatty acid alkyl esters particularly include the fatty acid alkyl ester obtained by reacting alcohol with triglyceride extracted from the same triglyceride-containing parts of oil-bearing plant.
Patent NZ-561172-A (NZ)
Title: A connection socket for a concrete reinforcement elements
Inventor: LAWLEY DEREK TRENT
IPC: E04B5/16
Filed: 2007-09-05
Abstract: A cast-in connection member 2 for pre-fabricated cementitious building elements the connection member 2 being adapted to receive a connection element comprising a shaft and a head formed on at least one end of the shaft, characterised in that the connection member 2 defines an internal volume comprising an insertion zone 5A and a retention zone 5 in communication with the insertion zone 5A, the insertion zone 5A is adapted to receive the head of the connection element, and the retention zone 5 is adapted to receive and retain the head of the connection element within the retention zone 5 by one or more surfaces bearing against the head or foot of the connection element.
Patent NZ-566547-A (NZ)
Title: Communications systems firewall
Inventor: WISEMAN SIMON ROBERT
IPC: H04L29/06
Filed: 2006-09-12
Abstract: A communications system comprises a filter having an input channel and an output channel; an operating system having an input channel coupled to the output channel of the filter, and an output channel; a receiver coupled at an upper interface to the operating system below and at a lower interface to a content checker above and a protocol stack coupled at a lower interface to the operating system below and at an upper interface to the content checker above; The content checker is configured to receive data from the upper interface of the receiver and to forward the data to the upper interface of the protocol stack responsive to content checks applied to said data. The receiver is configured to forward to the content checker only data received from the operating system which is contained in network layer protocol data units each consisting of a protocol frame, cell, or packet which is invalid with respect to the protocol stack and the filter is arranged to forward to the operating system only network layer protocol data units which are invalid with respect to the protocol stack.
Patent NZ-566949-A (NZ)
Title: A ground-fault circuit-interrupter system for three-phase electrical power systems
Inventor: HAMMER PAUL S
IPC: H02H3/00
Filed: 2006-10-03
Abstract: A ground-fault circuit-interrupter (GFCI) system for a separately derived three-phase electrical power supply system is disclosed. The power supply system includes a three-phase power supply and main bus circuit with a plurality of feeder circuits connected to the main bus circuit. The GFCI comprises a plurality of GFCI and a processor. Each GFCI unit is associated with either the main bus circuit or a respective one of the feeder circuits and operative to monitor the capacitive charging currents or the fault current to ground flowing therethrough and to generate a fault signal commensurate with the degree of unbalance of the currents flowing through the several conductors of each the circuit.; and The processor is for continuously monitoring the fault signals generated by the GCFI unit on the main bus circuit and the GCFI unit on each feeder circuit connected to the main bus circuit. The processor is programmed to determine when a fault condition exists based on certain predetermined relationships between and among the fault signal generated by the GFCI unit in the main bus circuit and the fault signals generated by the GFCI units in the feeder circuits, to determine which circuit is experiencing a fault, to generate and transmit a trip signal to the GFCI unit in the faulted circuit causing that circuit to be interrupted, and to generate and transmit an inhibit signal to at least some of the other circuits causing those circuits to be inhibited from interruption.
Patent NZ-567290-A (NZ)
Title: Carbamazepine-cyclodextrin complex for parenteral administration
Inventor: CLOYD JAMES
IPC: A61K31/55
Filed: 2006-10-02
Abstract: Disclosed is a carbamazepine-cyclodextrin composition for parenteral administration to a human in need thereof comprising 5 to about 50 mg/ml carbamazepine complexed with a sulfoalkyl-cyclodextrin. Also disclosed is the use of said carbamazepine-cyclodextrin composition in the manufacture of a medicament for the treatment of a disorder selected from the group consisting of seizure disorders, neuralgia, bipolar disorders, psychiatric disorders, neurogenic diabetes insipidus, dyscontrol syndrome, alcohol withdrawal, fibromyalgia, neuropathy, status epilipticus, or refractory seizure disorders.
Patent NZ-567844-A (NZ)
Title: Preparation, comprising iron (III) complex compounds and redox-active substances
Inventor: ZIEGLER PRISKA
IPC: A61K31/295
Filed: 2006-08-22
Abstract: Disclosed is a preparation comprising one or more iron(III) complex compounds with carbohydrates, the complex compounds having a redox potential at pH 7 of from -324 mV to -750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers of pullulans and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid, vitamin E, cysteine, physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones, and glutathione, wherein the preparation is for oral administration. Also disclosed is the use of said preparation in the treatment of chronic inflammatory bowel disease or restless leg syndrome.
Patent NZ-575469-A (NZ)
Title: Agent comprising lactobacillus for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor
Inventor: KAWAKAMI HIROSHI
IPC: A61K35/747
Filed: 2007-08-30
Abstract: Provided is the use of cells or a culture of cells of Lactobacillus gasseri for the manufacture of a medicament for increasing blood adiponectin concentration or inhibiting a decrease in blood adiponectin concentration in a patient having a disease associated with abnormal blood adiponectin concentration. The disease may be the metabolic syndrome.
Patent NZ-575974-A (NZ)
Title: Use of human cells of myeloid leukaemia origin for expression of antibodies
Inventor: GOLETZ STEFFEN
IPC: C07K14/59
Filed: 2007-09-10
Abstract: Disclosed is an isolated immortalized human blood cell selected from the group consisting of NMH9D8 [DSM ACC 2806], NM-H9D8-E6 [DSM ACC 2807], NM-H9D8-E6Q12 [DSM ACC 2856] or a cell or cell line derived therefrom, which is capable of producing a protein molecule composition having the following glycosylation characteristics: (i) it comprises no detectable NeuGc; (ii) it comprises no detectable terminal Galalpha1-3Gal; (iii) it comprises at least 2% carbohydrate structures of the total carbohydrate units or of at least one particular carbohydrate chain at a particular glycosylation site of a protein molecule of the protein molecules in said protein molecule composition which contains bisecting GlcNAc; (iv) it comprises alpha2-6 linked NeuNAc; (v) it has an increased sialylation degree with an amount of NeuNAc on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 15% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr [ATCC No. CRL-9096] when expressed therein. Further disclosed is a method for producing a protein molecule composition, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition; Wherein the host cell is a cell as defined above.
Patent NZ-576068-A (NZ)
Title: Printing material container, and board mounted on printing material container
Inventor: ASAUCHI NOBORU
IPC: B41J2/01
Filed: 2006-12-15
Abstract: A printing material container 100 detachably attachable to a printing apparatus having a plurality of apparatus-side terminals, the printing material container 100 comprising a terminal group 200 that includes a plurality of first terminals, a second terminal and a third terminal, wherein the first terminals respectively include a first contact portion for contacting a corresponding terminal among the plurality of apparatus-side terminals, the second terminal includes a second contact portion for contacting a corresponding terminal among the plurality of apparatus-side terminals, the third terminal includes a third contact portion for contacting a corresponding terminal among the plurality of apparatus-side terminals, and the second contact portion is located adjacent to the third contact portion, and wherein the first, second and third terminals are arranged such that, when the printing material container 100 is attached to the printing apparatus in use the plurality of first terminals receive signals for a first device, the second terminal receives a signal for a second device, a voltage applied to the second device is higher than a voltage applied to the first device, a ground voltage is applied to the third terminal, and the third terminal is used for detecting a contact between the third terminal and the corresponding apparatus-side terminal. (62) Divided Out of 564406
Patent NZ-579684-A (NZ)
Title: Fire damper seal with flat central portion connected to foot or feet by return portions to allow close contact with bladed even during blade twising
Inventor: HOLDER GARY BRIAN
IPC: E06B5/16
Filed: 2010-09-14
Abstract: A damper seal is shown installed in a fire damper assembly, and is shown in a plan view. Fire damper 2 is of pivoted blade construction and drops when a fusible link (not shown) breaks. The seal has a central portion 12 and end portions 15 spaced from the frame side 5,6. Returns 14 connect end portions 15 to feet 13 which are fixed to flanges 21, so that central portion 12 is biased against damper blade 2.